Time-Limited Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Who Have Undetectable MRD – Primary Analysis from the Randomized Phase II Vision HO141 Trial

  • Carsten Utoft Niemann (Speaker)
  • Julie Dubois (Co-author)
  • Christian Brieghel (Co-author)
  • Sabina Kersting (Co-author)
  • Lisbeth Enggaard (Co-author)
  • Gerrit J Veldhuis (Co-author)
  • Rogier Mous (Co-author)
  • Clemens Mellink (Co-author)
  • Johan A Dobber (Co-author)
  • Christian Bjørn Poulsen (Co-author)
  • Frederiksen, H. (Co-author)
  • Ann Janssens (Co-author)
  • Ida Schjødt (Co-author)
  • Ellen C Dompeling (Co-author)
  • Juha Juha Ranti (Co-author)
  • Mattias Mattsson (Co-author)
  • Mar Bellido (Co-author)
  • Kazem Nasserinejad (Co-author)
  • Hoa Thi Tuyet Tran (Co-author)
  • Mark-David Levin (Co-author)
  • Arnon P. Kater (Co-author)

Activity: Talks and presentationsConference presentations

Period11. Dec 2021
Event title63rd ASH Annual Meeting.
Event typeConference
LocationAtlanta, United States